Review of the Patient Burden and Therapeutic Landscape of Irritable Bowel Syndrome with Constipation in the United States [Corrigendum]

Figure 2 Treatment recommendations for IBS-C according to current US guidelines.^1,62,63 Note that although tegaserod is included in the guidelines, it has been omitted from this figure as it has been withdrawn from the market and is unavailable for prescription. ^aLifestyle modification suggested by the AGA: exercise, sleep, stress reduction. ^bAt the time of preparation of the most recent ACG guidelines, the amount of real-world clinical practice experience with tenapanor available for consideration by the ACG would have been limited (tenapanor received FDA approval for use in 2019).

Abbreviations: ACG, indicates American College of Gastroenterology; AGA, American Gastroenterological Association; CBT, cognitive behavioral therapy; FDA, Food and Drug Administration; FODMAP, fermentable oligosaccharides, disaccharides, monosaccharides, and polyols; IBS, irritable bowel syndrome; OTC, over-the-counter; PEG, polyethylene glycol; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; US, United States.